To get insight into the role of CD95 in GBM, we analyzed a data set accessible via The Cancer Genome Atlas (TCGA) featuring expression as well as clinical patient data.26 When compared with unmatched, non-tumor controls, CD95 was found to be highly overexpressed in GBM patient samples (Figure 1a). The gene discussed is FAS; the disease is glioblastoma.